

PRESS RELEASE

Stockholm, August 27, 2018

BIOLAMINA announces an OEM partnership with CELLINK for the development of biologically relevant bioink products for bioprinting

Two innovative companies with unique technologies unite, creating powerful tools for researches and companies developing the treatments of tomorrow.

During recent years, 3D-Bioprinting has emerged as a powerful cell culture technology but has also been hampered by the lack of a biologically relevant Bioink. Today, CELLINK launches a brand new Bioink containing BIOLAMININS, that will enable scientists to combine the unique properties of the laminin protein with culturing cells in a 3D-environment. This approach will advance the 3D-Bioprinting technology since the biological effect of the laminin protein will improve the structure and biochemical features, creating a microenvironment more authentic to the *in vivo* setting.

BIOLAMINA develops and manufactures laminin protein-based reagents, BIOLAMININS. Laminins are a key regulator of cell behavior and essential for maintaining tissue functions. The impact of BIOLAMININ matrices on the advances in cell-based research and for the development of reliable and robust processes for cell therapy applications have been published in many high-impact journals.

"We are excited to announce this collaboration with Cellink and to get additional user applications for our outstanding products" says Kristian Tryggvason, CEO of BIOLAMINA. "This collaboration is in line with our vision to provide the research community with tools to enable new cell assays, to revolutionize cell culture."

"We are stoked to be working together with one of the leading companies in the field of laminins as it will ensure our customers and partners will continue to get the highest quality products and reagents for their research. As a leading bioprinting technology provider, it's essential to continue innovating and offering bioink products that create added value for our users. Our product development is always customer demand based and it's a pleasure seeing this collaboration bringing new products to fruition", says Erik Gatenholm, CEO of Cellink.

For more information, please contact:

BIOLAMINA AB
Kristian Tryggvason, CEO Telephone +46 70 743 2233
E-mail: communications@biolamina.com

Press images: www.biolamina.com/press-room-images



About BIOLAMINA

BioLamina commercializes innovations that solves technical problems associated with culturing of embryonic stem cells and other types of primary cells, such as low cell growth and quality. The company built on a scientific foundation within matrix biology and cell culture based research. Many of the products manufactured and sold by BIOLAMINA are based on human recombinant proteins called laminins. By covering surfaces used for cell culture with recombinant laminins, the cell's natural environment in the body is mimicked, allowing the cells to thrive and maintain their function. With the introduction of BIOLAMINA's products, scientists now have more powerful resources to develop their cultivation systems, enabling clinical development and the production of new cell therapies.

For more information: www.biolamina.com

About CELLINK

Cellink has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser.

For more information: www.cellink.com

